Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies

• US 20100048523A1
• Filed: 04/06/2007
• Published: 02/25/2010
• Est. Priority Date: 04/07/2006
• Status: Abandoned Application

• Current Assignee: Johns Hopkins University, University of Maryland Baltimore County (University of Maryland)
• Original Assignee: Johns Hopkins University
• Inventors: Bachman, Kurtis E., Park, Ben Ho
• Application Number:
  US12/296,277
• Publication Number:
  US 20100048523A1
• Time in Patent Office: Days
• US Class Current: 514/174
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A composition and method of using are provided, which composition includes: at least one compound selected from the group including a compound having formula (I), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof, the compounds being described herein, and a combination thereof, and at least one pharmaceutically acceptable carrier; wherein the composition is suitable for administration to a mammal. Methods of using the compound are also provided.

Claims

1. A composition, comprising:

at least one compound selected from the group consisting of a compound having formula (1), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof; and

at least one pharmaceutically acceptable carrier;

wherein the composition is suitable for administration to a mammal;

wherein the compound having formula (I) is;

and wherein the compound having formula (II) is;

2. The composition of claim 1, wherein the compound is the compound having formula (I), a salt thereof, a prodrug thereof, or a combination thereof.

3. The composition of claim 1, wherein the compound is the compound having formula (II), a salt thereof, a prodrug thereof, or a combination thereof.

4. The composition of claim 1, wherein the compound having formula (I) has the following structure:

5. The composition of claim 1, wherein the compound having formula (II) has the following structure:

6. The composition of claim 1, wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of water, physiological saline, ethanol, aqueous ethanol, dimethyl sulfoxide, castor oil, benzyl alcohol, benzyl benzoate, albumin, polyethylene glycol, cellulose, fatty acid, methylcellulose, dextrose, glycerol, mannitol, lactose, starch, magnesium stearate, sodium saccharin, magnesium carbonate, and a combination thereof.

19. A method for manufacturing a medicament suitable for treating a mammal having a hormonal dependent malady, comprising contacting the compound of claim 1 with at least one pharmaceutically acceptable carrier to form a composition suitable for administration to the mammal.

7. A method, comprising:

administering, to a mammal, at least one compound selected from the group consisting of a compound having formula (I), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof;

wherein the compound having formula (I) is;

and wherein the compound having formula (II) is;

8. The method of claim 7, wherein the mammal is known to have a hormonal dependent malady.

9. The method of claim 7, wherein the mammal is known to have a hormonal dependent malady selected from the group consisting of cancer, Tamoxifen-resistant cancer, Tamoxifen resistant breast cancer, hormone-dependent breast cancer, hormone-dependent endometrial cancer, hormone-dependent ovarian cancer, estrogen receptor expressing cancer, progesterone receptor expressing cancer, vaginitis, vaginal dryness, post-menopausal vaginitis, osteoporosis, cardiovascular disease, decreased fertility, infertility, and a combination thereof.

10. The method of claim 7, wherein the mammal is in need of a contraceptive.

11. The method of claim 7, wherein the mammal is a human.

12. The method of claim 7, wherein the mammal is a female human.

13. The method of claim 7, wherein the compound is administered in the form of a composition, said composition comprising:

the at least one compound selected from the group consisting of a compound having formula (I), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof; and

at least one pharmaceutically acceptable carrier.

14. The method of claim 7, wherein the compound is the compound having formula (I), a salt thereof, a prodrug thereof, or a combination thereof.

15. The method of claim 7, wherein the compound is the compound having formula (II), a salt thereof, a prodrug thereof, or a combination thereof.

16. The method of claim 7, wherein the compound having formula (I) has the following structure:

17. The method of claim 7, wherein the compound having formula (II) has the following structure:

18. The method of claim 13, wherein the pharmaceutically acceptable carrier comprises at least one selected from the group consisting of water, physiological saline, ethanol, aqueous ethanol, dimethyl sulfoxide, castor oil, benzyl alcohol, benzyl benzoate, albumin, polyethylene glycol, cellulose, fatty acid, methylcellulose, dextrose, glycerol, mannitol, lactose, starch, magnesium stearate, sodium saccharin, magnesium carbonate, and a combination thereof.